Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Neoantigen compositions and methods of using the same in immunooncotherapy

An antigen, cancer antigen technology, applied to the cancer antigenic peptides of MHC II peptides, outlined
The invention provides, field of invention, can solve the problems such as limited curative effect of cancer therapy

Inactive Publication Date: 2018-12-21
OCEANSIDE BIOTECH
View PDF18 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, to date, many cancer therapies have had limited efficacy due to the severity of side effects and systemic toxicity

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Neoantigen compositions and methods of using the same in immunooncotherapy
  • Neoantigen compositions and methods of using the same in immunooncotherapy
  • Neoantigen compositions and methods of using the same in immunooncotherapy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach

[0285] Embodiments encompassed by the present invention include the following embodiments P1-PX28.

[0286] Embodiment P1. A protein comprising a cancer antigenic peptide covalently attached to a mature MHC class II peptide capable of non-covalently directly binding to the MHC class II peptide.

[0287] Embodiment P2. The protein of Embodiment P1, wherein said cancer antigenic peptide is N-terminal to said mature MHC class II peptide.

[0288] Embodiment P3. The protein of one of embodiments P1 or P2, further comprising a peptide linker covalently linking said cancer antigenic peptide and said mature MHC class II peptide.

[0289] Embodiment P4. The protein of embodiment P3, wherein said peptide linker consists of one or more glycines, one or more serines, or a combination of one or more glycines and one or more serines.

[0290] Embodiment P5. The protein of one of embodiments P1-P4, further comprising a signal peptide covalently attached to the N-terminus of said cance...

Embodiment approach P8

[0293] Embodiment P8. The protein of one of embodiments P1-P6, wherein said cancer antigenic peptide is 15-24 amino acids in length.

Embodiment approach P9

[0294] Embodiment P9. An antigen presenting cell comprising the protein of one of embodiments P1-P8.

[0295] Embodiment P10. The antigen presenting cell of embodiment P9, wherein said protein is located on the cell surface of said antigen presenting cell.

[0296] Embodiment P11. The antigen presenting cell of embodiment P9 or P10, wherein said antigen presenting cell is a dendritic cell or a B cell.

[0297] Embodiment P12. The antigen presenting cell of embodiment P9 or P10, wherein said antigen presenting cell is a dendritic cell.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
diameteraaaaaaaaaa
Login to View More

Abstract

Provided herein are, inter alia, compositions including a fusion protein containing an antigenic cancer peptide and a mature MHC class II peptide, a nucleic acid encoding the protein, a pharmaceuticalformulation thereof, an antigen-presenting cell expressing the protein. Also provided herein are methods for treating cancer utilizing these compositions.

Description

[0001] Cross References to Related Applications [0002] This application claims priority and benefit to U.S. Provisional Patent Application 62 / 298,275 filed February 22, 2016, the contents of which are incorporated by reference in their entirety for all purposes. [0003] REFERENCE TO SEQUENCE LISTING, TABLE OR COMPUTER PROGRAM LISTING APPENDIX FILLED IN ASCII [0004] The sequence listing written in file 49906-503001WO_ST25.TXT, 29,951 bytes machine format IBM-PC, MS-Windows operating system, created on February 22, 2017 is hereby incorporated by reference. Background of the invention [0005] Over the past few decades, the vast majority of research has contributed significantly to understanding the molecular mechanisms that lead to cancer. However, such scientific advances in the field of molecular oncology have not paralleled corresponding advances in cancer treatment. In most patients, surgery and / or radiation therapy remain the main modalities for local treatment of ca...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/00C07K14/47C12N15/12
CPCC07K14/47C07K14/70539A61K2039/53A61K2039/605C07K2319/40A61P35/00A61P37/02A61K39/4622A61K39/4611A61K39/464401A61K2039/5154A61K2039/5158A61K39/0011
Inventor D·W·埃特尔
Owner OCEANSIDE BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com